SCHEMBL1700855

SCHEMBL1700855

Cc1cccc(NC(c2ccccn2)c2ccc3cccnc3c2O)n1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.79
MAPT P10636 3/20 0.79
SMN1; SMN2 Q16637 3/20 0.79
KDM4E B2RXH2 1/20 0.79
USP2 O75604 1/20 0.79
LMNA P02545 1/20 0.79
ALOX15 P16050 1/20 0.79
NFKB1 P19838 1/20 0.79
MAPK1 P28482 1/20 0.79
HTT P42858 1/20 0.79
PPP1CA P62136 1/20 0.79
NFKB2 Q00653 1/20 0.79
RELA Q04206 1/20 0.79
NPSR1 Q6W5P4 1/20 0.79
TDP1 Q9NUW8 1/20 0.79
L3MBTL1 Q9Y468 1/20 0.79
GRK6 P43250 2/20 0.70
MDM2 Q00987 6/20 0.69
P4HB P07237 1/20 0.63
CD74 P04233 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15783167 0.92 MAPT (0.70) TP53MAPTSMN1; SMN2KDM4EUSP2
SCHEMBL16810181 0.88 TP53 (1.00) TP53MAPTSMN1; SMN2KDM4EUSP2
SCHEMBL18197735 0.88 TP53 (0.79) TP53MAPTSMN1; SMN2KDM4ELMNA
SCHEMBL18131609 0.87 MDM2 (0.76) TP53MAPTSMN1; SMN2KDM4EUSP2
SCHEMBL1700871 0.87 MDM2 (0.76) TP53MAPTSMN1; SMN2KDM4EUSP2
SCHEMBL18131661 0.87 MDM2 (0.76) TP53MAPTSMN1; SMN2KDM4EUSP2
SCHEMBL18131660 0.86 MDM2 (0.63) TP53MAPTSMN1; SMN2KDM4EUSP2
SCHEMBL19092983 0.86 MDM2 (0.63) TP53MAPTSMN1; SMN2KDM4EUSP2
SCHEMBL21519373 0.86 MDM2 (0.63) TP53MAPTSMN1; SMN2KDM4EUSP2
SCHEMBL16810106 0.85 MAPT (0.79) TP53MAPTSMN1; SMN2KDM4EUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566849-A1 8-HYDROXY-QUINOLINE DERIVATIVES "Avidin" Kutató, Fejleszt És Kereskedelmi Korlatolt Felelossegu Tarsasag (HU) 2013-03-13 EP claimed
WO-2011148208-A1 8-HYDROXY-QUINOLINE DERIVATIVES "AVIDIN" KUTATÓ, FEJLESZTŐ ÉS KERESKEDELMI KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG (HU) 2011-12-01 WO claimed
EP-3079697-B1 PROLYLHYDROXYLASE/ATF4 INHIBITORS FOR TREATING NEURAL CELL INJURY UNIV CORNELL (US) 2021-02-03 EP disclosed
US-20200360366-A1 PROLYLHYDROXYLASE/ATF4 INHIBITORS AND METHODS OF USE FOR TREATING NEURAL CELL INJURY OR DEATH AND CONDITIONS RESULTING THEREFROM CORNELL UNIVERSITY (US) 2020-11-19 US disclosed
EP-2566849-B1 8-HYDROXY-QUINOLINE DERIVATIVES AVIDIN KUTATO FEJLESZTOE ES KERESKEDELMI KORLATOLT FELELOESSEGUE TARSASAG (HU) 2019-09-18 EP disclosed
EP-2566849-B1 8-HYDROXY-QUINOLINE DERIVATIVES AVIDIN KUTATO FEJLESZTOE ES KERESKEDELMI KORLATOLT FELELOESSEGUE TARSASAG (HU) 2019-09-18 EP disclosed
US-20150272939-A1 Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase YALE UNIVERSITY (US) 2015-10-01 US disclosed
US-20150272939-A1 Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase YALE UNIVERSITY (US) 2015-10-01 US disclosed
WO-2015089416-A1 PROLYLHYDROXYLASE/ATF4 INHIBITORS FOR TREATING NEURAL CELL INJURY CORNELL UNIVERSITY (US) 2015-06-18 WO disclosed
US-8871937-B2 8-hydroxy-quinoline derivatives “AVIDIN” Kutato, Fejleszto es Kereskedelmi Korlatolt Felelossegu Tarsasag (HU) 2014-10-28 US disclosed
US-8871937-B2 8-hydroxy-quinoline derivatives “AVIDIN” Kutato, Fejleszto es Kereskedelmi Korlatolt Felelossegu Tarsasag (HU) 2014-10-28 US disclosed
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG (HU) 2013-05-23 US disclosed
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG (HU) 2013-05-23 US disclosed
WO-2011148208-A1 8-HYDROXY-QUINOLINE DERIVATIVES "AVIDIN" KUTATÓ, FEJLESZTŐ ÉS KERESKEDELMI KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG (HU) 2011-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200360366-A1 PROLYLHYDROXYLASE/ATF4 INHIBITORS AND METHODS OF USE FOR TREATING NEURAL CELL INJURY OR DEATH AND CONDITIONS RESULTING THEREFROM ATF4, P4HTM, P4HA1 TP53 2913/4885MAPT 1958/4885SMN1; SMN2 130/4885
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES CYP2C8, NQO1, KEAP1 TP53 4173/4885MAPT 2319/4885SMN1; SMN2 1845/4885
US-20150272939-A1 Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase KDM1B, KDM1A, JMJD1C TP53 3089/4885MAPT 4286/4885SMN1; SMN2 3955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.